Affimed to Collaborate with Merck to Evaluate AFM13 in Combination with KEYTRUDA for Patients with Hodgkin Lymphoma

By: via Benzinga
Affimed N.V. (Nasdaq: AFMD) announced today that it has entered into a clinical research collaboration in immuno-oncology with Merck ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.